MLTX ALERT: Did MoonLake Immunotherapeutics Mislead Investors? BFA Law Reminds Investors with Losses of the Upcoming December 15 Court Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences compared to traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted nearly 90%, from $61.99 to $6.24 per share [6].